EZH2 and familial pancreatic carcinoma: ANLN induced EZH2 upregulation and is involved in pancreatic cancer progression by mediating the miR-218-5p/LASP1 signaling axis, EZH2 upregulation or miR-218-5p downregulation, and LASP1 partially contributes to reversing the anti-tumour effect of ANLN deficiency on pancreatic cancer cell development [5].